Abstract |
Itraconazole, the first orally active triazole antifungal agent, was tested in 185 cases of acute or chronic (recurrent) dermatophytosis. The skin infections were divided into two major diagnostic groups: tinea corporis/ tinea cruris (91 cases) and tinea pedis/ tinea manuum (94 cases). Each patient was randomly assigned to a regimen of 50 or 100 mg of itraconazole daily. Of the cases of tinea corporis and/or tinea cruris, 94% responded to 50 mg of itraconazole daily and 96% to 100 mg daily. The effects of therapy were evident earlier when 100 mg daily was given. Of the cases of tinea pedis and/or tinea manuum, 80% responded to 50 mg of itraconazole daily and 94% to 100 mg. Again, improvement was seen sooner with the 100-mg regimen. Only five patients (2.9%) reported minor adverse reactions. Hematologic and blood-biochemical parameters were monitored before treatment and at biweekly intervals thereafter in 37 patients; no significant abnormalities were observed. Thus, either 50 or 100 mg of itraconazole daily constitutes effective treatment for dermatophytoses. Since the larger dosage induces a faster response, it should be evaluated further.
|
Authors | H Degreef, K Mariën, H De Veylder, K Duprez, A Borghys, L Verhoeve |
Journal | Reviews of infectious diseases
(Rev Infect Dis)
1987 Jan-Feb
Vol. 9 Suppl 1
Pg. S104-8
ISSN: 0162-0886 [Print] United States |
PMID | 3027832
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antifungal Agents
- Itraconazole
- Ketoconazole
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antifungal Agents
(administration & dosage, therapeutic use)
- Child
- Drug Administration Schedule
- Female
- Humans
- Itraconazole
- Ketoconazole
(administration & dosage, analogs & derivatives, therapeutic use)
- Male
- Middle Aged
- Random Allocation
- Tinea
(drug therapy)
|